IPP Bureau
Torrent Pharma secures Rs. 12,500 crore for JB Chemicals takeover
By IPP Bureau - January 18, 2026
The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers
JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr
By IPP Bureau - January 18, 2026
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation
By IPP Bureau - January 17, 2026
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
HDFC Bank to rally 1,500 staff at Tata Mumbai Marathon 2026 to drive cancer awareness
By IPP Bureau - January 17, 2026
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy
By IPP Bureau - January 17, 2026
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
Rakuten Medical teams up with LOTTE Biologics to boost production of innovative cancer therapy
By IPP Bureau - January 17, 2026
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
Agno Pharma acquires Actylis Eugene, expanding US API manufacturing footprint
By IPP Bureau - January 17, 2026
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer
By IPP Bureau - January 17, 2026
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Boston Scientific to acquire Penumbra in $14.5 billion deal
By IPP Bureau - January 17, 2026
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
Miach Orthopaedics’ BEAR implant gains FDA label claim for reduced arthritis risk
By IPP Bureau - January 17, 2026
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
GCCL & OPIS forge global clinical trial alliance
By IPP Bureau - January 17, 2026
WuXi Biologics launches PatroLab digital twin platform to transform biologics manufacturing
By IPP Bureau - January 16, 2026
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
Alphatec and Theradaptive forge landmark spine partnership as Series B round launches
By IPP Bureau - January 16, 2026
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
Redesigned brain receptor drugs show promise for depression
By IPP Bureau - January 16, 2026
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
AVEO Oncology doses first patient in pioneering AML clinical trial
By IPP Bureau - January 16, 2026
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
